Skip to main content

Table 3 Baseline characteristics

From: Glycoprotein IIb/IIIa inhibitors for cardiogenic shock complicating acute myocardial infarction: a systematic review, meta-analysis, and meta-regression

Analysis

GPI

Standard treatment

MD

95% CI

P value

I2 (%)

Age

66.6 ± 12.6

69.1 ± 12.3

− 2.75

− 0.64 to 0.83

0.13

74

LVEF

35 ± 9

32 ± 10

0.33

− 1.83 to 2.49

0.63

27

Analysis

GPI

Standard treatment

OR

95% CI

P value

I2 (%)

Gender (male)*

470/640

258/397

1.43

1.09–1.89

0.01

8

Diabetes mellitus

112/470

90/306

0.77

0.55–1.08

0.13

0

Hypertension*

247/425

168/225

0.68

0.49–0.94

0.02

74

Tobacco use*

197/470

87/306

1.87

1.20–2.91

0.006

36

Previous MI

82/470

77/306

0.75

0.48–1.18

0.21

25

3 vessel disease

181/425

124/225

0.64

0.29–1.45

0.29

79

Left main lesion

74/446

31/298

1.54

0.52–4.57

0.44

76

Invasive ventilation

312/586

198/338

1.20

0.62–2.23

0.57

65

IABP

363/640

149/397

2.13

0.96–4.72

0.06

82

TIMI 0/1 pre-procedure

167/595

185/346

0.60

0.19–1.88

0.38

90

  1. Bernat et al.’s study did not provide information regarding baseline data and was therefore not included in the baseline characteristics analysis
  2. GPI glicoprotein IIb/IIIa inhibitors, MD mean difference, CI confidence intervals, OR odds ratio, LVEF left ventricular ejection fraction, MI myocardial infarction, IABP intraortic balloon pump, TIMI thrombolysis in myocardial infarction